Gregory Stokes JD

Gregory Stokes JD General Information

Biography

Mr. Gregory Stokes served as Operating Team Member at 1315 Capital. He also served as Board Member at Sienna Labs. From 2008 to 2011 he served as Executive Vice President of Business Development at Oceana Therapeutics, a global healthcare company focused on colorectal, gastroenterology and urological diseases. He played a key role in the sale of Oceana to Salix Pharmaceuticals for $300M. Prior to Oceana, he served as President and Chief Operating Officer of Esprit Pharma, a specialty pharmaceutical company focusing in the genito-urinary therapeutic area. Under his leadership, Esprit grew to over $50 million in revenues and deployed a sales force of over 200 reps before being acquired in 2007 by Allergan. Previously, he served as Vice President of Corporate Development for ESP Pharma, a specialty pharmaceutical company founded in 2002 to focus on the acute-care market. At ESP, he was in the forefront of identifying and completing acquisition transactions contributing to the growth of the company's portfolio of products and development drugs. Additionally, he played a key role in the sale of ESP in 2005 for over $500 million. Prior to ESP, Greg served as Director of Business Development with Shire plc where he executed business development strategies with regard to in- and out-licensing prospects, joint ventures, acquisitions, co-promotion and co-marketing arrangements and investments in late-stage pipeline compounds. Previously, he was employed by Roberts Pharmaceutical Corporation which merged into Shire at year-end 1999. While at Roberts, Greg advanced in position from a Specialty Hospital Sales Representative to Senior Manager, Business Development and Strategic Planning. Prior to Roberts, he served as a Sales Representative for Reed & Carnrick Pharmaceuticals, a division of Block Drug, which was acquired by German based Schwarz Pharma AG. He holds a B.A. degree from the University of Pennsylvania and received his MBA and J.D. degrees from Rutgers University. He has extensive international pharmaceutical experience and was admitted to the New Jersey State Bar in 1999.